On February 18th, 2020 Gain Therapeutics SA was invited to present its proprietary platform technology, SEE-Tx, and its applications in rare and genetic CNS diseases at the Keystone Symposia in Brain Therapeutics in Santa Fe, USA. Using the 3D structure of proteins and proprietary computational technology, the SEE-Tx platform identifies and exploits previously uncharacterised binding sites that are druggable but do not bind the natural substrate. By focusing on non-conventional binding sites, Gain Therapeutics has identified ad hoc structurally targeted allosteric regulators (STARs) which are able to stabilize misfolding mutations, restore targeted protein’s enzymatic activity and reduce accumulation of toxic substrates.
Gain Therapeutics SA has been invited to present recent developments on its STARs program targeting GM1 gangliosidosis and Morquio B disorders at the WORLDSymposium in Orlando. On February 13th, 2020 Gain Therapeutics shared recent data on how its STARs molecules can properly support protein folding, enzyme gain of function and toxic substrate reduction in GLB1-related disorders.
Gain Therapeutics SA was pleased to present at the WORLDSymposium in Orlando data on how its STARs molecules are ameliorating the biodistribution of recombinant IDUA in mucopolysaccharidosis type 1 (MPS-I). On February 12th, 2020 Gain Therapeutics presented as late-breaking poster recent data on the development of a structurally targeted allosteric modulator administered in combination with laronidase (marketed as Aldurazyme®) to improve its biodistribution to bones and cartilages in the treatment of MPS-I.
Gain Therapeutics SA was honored to present recent R&D developments on its STARs programs at the BIO CEO & Investor Conference held in New York on February 10th, 2020. In this occasion, Gain Therapeutics joined the investor and pharma community to discuss and address partnership opportunities to accelerate the development of Gain’s pipeline for rare and genetic CNS diseases.
San Francisco (USA), 12th-16th January 2020: Recent R&D achievements in the development of structurally targeted allosteric modulators for our most advanced rare genetic disease programs including GBA and GLB1 as well as IDUA combination therapy were shared and future investment and/or partnership opportunities addressed during the 3rd Annual Neuroscience Innovation Forum for business development, licensing & investment and the J.P. Morgan 38th Annual Healthcare Conference.
Gain Therapeutics SA is honored and pleased to have been accepted as a member of Farma Industria Ticino (FIT). The association counts 32 member companies, with a combined workforce of over 2900 employees and a total annual turnover of approximately 2.45 Billion Swiss Francs (>80% export), accounting for approximately 8.5% of the cantonal GNP.
Gain Therapeutics SA attended the Jefferies 2019 London Healthcare Conference on 20th-21st November, 2019. In this occasion, Gain Therapeutics discussed future developments in the treatment of rare genetic diseases targeting the central nervous system (CNS) and addressed short- and long-term investment opportunities with leading healthcare executives as well as institutional and venture capital investors
Gain Therapeutics SA was proud to join the 25th Annual International Partnering Conference Bio-Europe held in Hamburg, Germany on 11th-13th November, 2019. In this occasion, Gain Therapeutics shared recent R&D achievements and discussed future developments in the treatment of rare genetic diseases targeting the central nervous system (CNS).
On October 30th, 2019 Gain Therapeutics SA contributed with a determination sponsorship to the NTSAD’s annual Imagine & Believe event held in Cambridge, USA, which included high-caliber professionals, such as honorary guest Dr. Cynthia Tifft. NTSAD has been bringing together leaders in the rare disease community since 1957 and this annual meeting is a vital part of their ongoing effort to raise awareness as well as sustain and create partnerships. Gain Therapeutics is proud to share this mission and support NTSAD’s endeavors towards better treatment options for patients with Tay-Sachs, Canavan, Sandhoff, GM1 gangliosidosis and related diseases.
On October 29th, 2019 Gain Therapeutics SA, Neuro-Sys SAS and the Institute for Research in Biomedicine (IRB) successfully kicked off the European EUROSTARS project CHAPERONE. This project jointly addresses the challenges of developing innovative treatments for rare genetic diseases where there is either high unmet medical need or no available cure. At the project’s meeting held in Lugano the participants exchanged insightful information, planned upcoming activities and defined priorities for the project.
On September 25th, 2019 Gain Therapeutics presented its R&D programs and joined the panel discussion on the future of the CNS market and R&D landscape at the 19th Biotech in Europe Forum for Global Partnering & Investment in Basel.
On September 20th, 2019 Gain Therapeutics joined Cure GM1 Family Meeting 2019 to introduce its programs and efforts to support patients, families and researchers in their endeavors to meet patients' needs for cure and treatment. Dr. Manolo Bellotto presented Gain Therapeutics’s brain penetrant STAR molecules to reduce the burden of GM1 Gangliosidosis disease.
Gain Therapeutics SA’s poster “Brain penetrant structurally targeted allosteric regulators for treating Parkinson disease and other α-synucleopathies” was presented during the Synuclein Meeting (Sept 1-4th 2019) in Porto, Portugal.
announces that it has received funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA to advance its proprietary non-competitive pharmacological chaperones for Parkinson’s disease.